Cargando…

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

BACKGROUND: The KEYNOTE‐024 trial demonstrated that pembrolizumab, a PD‐1 inhibitor, significantly improves progression‐free survival (PFS) and overall survival (OS) in selected patients with previously untreated advanced non–small cell lung cancer (NSCLC) with a PD‐L1 tumor proportion score (TPS) ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amrane, Karim, Geier, Margaux, Corre, Romain, Léna, Hervé, Léveiller, Guillaume, Gadby, Florence, Lamy, Régine, Bizec, Jean‐Louis, Goarant, Eric, Robinet, Gilles, Gouva, Sylvie, Quere, Gilles, Abgral, Ronan, Schick, Ulrike, Bernier, Cyril, Chouaid, Christos, Descourt, Renaud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131849/ https://www.ncbi.nlm.nih.gov/pubmed/32022459 http://dx.doi.org/10.1002/cam4.2806

Ejemplares similares

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29)
por: Renaud, Emmanuelle, et al.
Publicado: (2023)

Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung
por: Agar, Camille, et al.
Publicado: (2020)

Vascular Acrosyndromes Associated With Prolonged Tumor Response in Advanced Lung Cancer Patients During Treatment With Antimetabolites: A Report of Two Cases
por: Geier, Margaux, et al.
Publicado: (2021)

Real‐life second‐line epirubicin–paclitaxel regimen as treatment of relapsed small‐cell lung cancer: EpiTax study
por: Annic, Josselin, et al.
Publicado: (2022)

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
por: Amrane, Karim, et al.
Publicado: (2019)

Henoch–Schönlein Purpura Associated with Lung Cancer: When Paraneoplastic Manifestations Impede Oncological Management
por: Philippe, Éloïse, et al.
Publicado: (2021)

Durvalumab‐induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non‐small cell lung cancer: A case report
por: Domblides, Maël, et al.
Publicado: (2021)

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study)
por: Corre, Romain, et al.
Publicado: (2018)

Case report: Eosinophilic fasciitis induced by pembrolizumab with high FDG uptake on (18)F-FDG-PET/CT
por: Amrane, Karim, et al.
Publicado: (2022)

Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer
por: Quéré, Gilles, et al.
Publicado: (2016)

False Positive 18F-FDG Positron Emission Tomography Findings in Schwannoma—A Caution for Reporting Physicians
por: Boré, Paul, et al.
Publicado: (2018)

Case Report: Coronaro-bronchial fistula vascularizing a squamous cell lung cancer
por: Ntshaykolo, Chloe, et al.
Publicado: (2023)

Case Report: Nasal Cavity Epithelial-Myoepithelial Carcinoma With High Fluoro-D-Glucose Uptake on Positron Emission Tomography/Computed Tomography
por: Dzuko Kamga, Jacques, et al.
Publicado: (2021)

Author Correction: Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
por: Amrane, Karim, et al.
Publicado: (2023)

Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer
por: Amrane, Karim, et al.
Publicado: (2023)

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
por: Amrane, Karim, et al.
Publicado: (2021)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

Targeted therapy for localized non-small-cell lung cancer: a review
por: Paleiron, Nicolas, et al.
Publicado: (2016)

Inter-observer and segmentation method variability of textural analysis in pre-therapeutic FDG PET/CT in head and neck cancer
por: Guezennec, Catherine, et al.
Publicado: (2019)

Lung Cancer in an Orthoprosthetist Using Vermiculite
por: Durand-Moreau, Quentin, et al.
Publicado: (2017)

Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review
por: Bourbonne, Vincent, et al.
Publicado: (2022)

Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy
por: Lucia, François, et al.
Publicado: (2022)

Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors
por: Thuillier, Philippe, et al.
Publicado: (2021)

Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study
por: Bourbonne, Vincent, et al.
Publicado: (2021)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
por: Monnet, Isabelle, et al.
Publicado: (2021)

Focus on treatment of lung carcinoid tumor
por: Noel-Savina, Elise, et al.
Publicado: (2013)

Morphometrics as an Insight Into Processes Beyond Tooth Shape Variation in a Bank Vole Population
por: Ledevin, Ronan, et al.
Publicado: (2010)

Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC
por: Roborel de Climens, Ferréol, et al.
Publicado: (2021)

Use of Baseline (18)F-FDG PET/CT to Identify Initial Sub-Volumes Associated With Local Failure After Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer
por: Lucia, François, et al.
Publicado: (2020)

Hotspot on 18F-FET PET/CT to Predict Aggressive Tumor Areas for Radiotherapy Dose Escalation Guiding in High-Grade Glioma
por: Allard, Bastien, et al.
Publicado: (2022)

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Pembrolizumab as a treatment for PML?: Waiting for Godot
por: Du Pasquier, Renaud A.
Publicado: (2019)

Diagnostic performance of a whole-body dynamic (68)GA-DOTATOC PET/CT acquisition to differentiate physiological uptake of pancreatic uncinate process from pancreatic neuroendocrine tumor
por: Thuillier, Philippe, et al.
Publicado: (2020)

Impact of suboptimal dosimetric coverage of pretherapeutic 18F-FDG PET/CT hotspots on outcome in patients with locally advanced cervical cancer treated with chemoradiotherapy followed by brachytherapy
por: Lucia, François, et al.
Publicado: (2020)

Starr–Edwards aortic valve: 50+ years and still going strong: a case report
por: Amrane, Mourad, et al.
Publicado: (2017)

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France
por: Atsou, Kokuvi, et al.
Publicado: (2016)

Integration of 18-FDG PET/CT in the Initial Work-Up to Stage Head and Neck Cancer: Prognostic Significance and Impact on Therapeutic Decision Making
por: Leclere, Jean-Christophe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_61ochhg9gngromnv1m8e1n9uo0